Weekly docetaxel/paclitaxel in pretreated metalistic breast cancer

Alessandra Gennari, Valentina Guarneri, Elisabetta Landucci, Cinzia Orlandini, Marianna Rondini, Barbara Salvadori, Sergio Ricci, Pier Franco Conte

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

The purpose of our study was to evaluate the feasibility and efficacy of weekly docetaxel/paclitaxel in pretreated advanced breast cancer patients. Twenty-six patients with metastatic breast cancer were included in this study. Three different schedules of treatment were administered. The starting schedule, A1, consisted of docetaxel 60 mg/m2 on day 1 plus paclitaxel 60 mg/m2 over 1 hour, weekly for 18 weeks; this schedule was considered feasible if at least 70% of the planned doses were given on time and without reduction. Schedule A2 consisted of the same doses administered on days 1 and 8 every 3 weeks, and schedule B consisted of docetaxel 25 mg/m2 followed by paclitaxel 40 mg/m2 for 1 hour on days 1 and 8 every 3 weeks for a total of 6 cycles. All patients had received prior anthracyclines, and 19 patients were pretreated with taxanes. Seventy-seven percent of patients had received at least 2 prior lines of chemotherapy. Twenty-five patients are assessable for toxicity and efficacy. A total of 109 cycles of chemotherapy have been administered, with a median of 4 cycles per patient (range, 1-8 cycles). The median delivered dose intensity was 27 mg/m2/week for paclitaxel (range, 18-50 mg/m2/week) and 17 mg/m2/week (range, 12-39 mg/m2/week) for docetaxel. Six patients received schedule A1. This schedule was considered not feasible due to neutropenia grade > 2, mucositis, and diarrhea grade 2, which required dose reduction/omission in 33% of administrations. For this reason, treatment in the following 5 patients was omitted on day 15 (schedule A2). Schedule B was found to be more feasible with 16% of dose reductions/omissions. The overall response rate was 68% (95%Cl, 50%-86%) with a median duration of response of 10 months (range, 2-18+ months). Treatment was well tolerated; myelosuppression was rare and grade 3 cutaneous toxicity was observed in only 2 patients. In conclusion, weekly docetaxel/paclitaxel is active at low dosages and was well tolerated as salvage chemotherapy in metastatic breast cancer. This regimen represents a valid option as a salvage treatment in taxane- and anthracycline-pretreated patients.

Original languageEnglish
Pages (from-to)346-352
Number of pages7
JournalClinical Breast Cancer
Volume3
Issue number5
Publication statusPublished - 2002

Fingerprint

docetaxel
Paclitaxel
Appointments and Schedules
Breast Neoplasms
Anthracyclines
varespladib methyl
Drug Therapy
Taxoids
Salvage Therapy
Mucositis

Keywords

  • Antracyclines
  • Granulocyte colony-stimulating factor
  • Neutropenia
  • Salvage chemotheraphy
  • Taxane

ASJC Scopus subject areas

  • Cancer Research

Cite this

Gennari, A., Guarneri, V., Landucci, E., Orlandini, C., Rondini, M., Salvadori, B., ... Conte, P. F. (2002). Weekly docetaxel/paclitaxel in pretreated metalistic breast cancer. Clinical Breast Cancer, 3(5), 346-352.

Weekly docetaxel/paclitaxel in pretreated metalistic breast cancer. / Gennari, Alessandra; Guarneri, Valentina; Landucci, Elisabetta; Orlandini, Cinzia; Rondini, Marianna; Salvadori, Barbara; Ricci, Sergio; Conte, Pier Franco.

In: Clinical Breast Cancer, Vol. 3, No. 5, 2002, p. 346-352.

Research output: Contribution to journalArticle

Gennari, A, Guarneri, V, Landucci, E, Orlandini, C, Rondini, M, Salvadori, B, Ricci, S & Conte, PF 2002, 'Weekly docetaxel/paclitaxel in pretreated metalistic breast cancer', Clinical Breast Cancer, vol. 3, no. 5, pp. 346-352.
Gennari A, Guarneri V, Landucci E, Orlandini C, Rondini M, Salvadori B et al. Weekly docetaxel/paclitaxel in pretreated metalistic breast cancer. Clinical Breast Cancer. 2002;3(5):346-352.
Gennari, Alessandra ; Guarneri, Valentina ; Landucci, Elisabetta ; Orlandini, Cinzia ; Rondini, Marianna ; Salvadori, Barbara ; Ricci, Sergio ; Conte, Pier Franco. / Weekly docetaxel/paclitaxel in pretreated metalistic breast cancer. In: Clinical Breast Cancer. 2002 ; Vol. 3, No. 5. pp. 346-352.
@article{8b4f319240334611b8f96d38246f5807,
title = "Weekly docetaxel/paclitaxel in pretreated metalistic breast cancer",
abstract = "The purpose of our study was to evaluate the feasibility and efficacy of weekly docetaxel/paclitaxel in pretreated advanced breast cancer patients. Twenty-six patients with metastatic breast cancer were included in this study. Three different schedules of treatment were administered. The starting schedule, A1, consisted of docetaxel 60 mg/m2 on day 1 plus paclitaxel 60 mg/m2 over 1 hour, weekly for 18 weeks; this schedule was considered feasible if at least 70{\%} of the planned doses were given on time and without reduction. Schedule A2 consisted of the same doses administered on days 1 and 8 every 3 weeks, and schedule B consisted of docetaxel 25 mg/m2 followed by paclitaxel 40 mg/m2 for 1 hour on days 1 and 8 every 3 weeks for a total of 6 cycles. All patients had received prior anthracyclines, and 19 patients were pretreated with taxanes. Seventy-seven percent of patients had received at least 2 prior lines of chemotherapy. Twenty-five patients are assessable for toxicity and efficacy. A total of 109 cycles of chemotherapy have been administered, with a median of 4 cycles per patient (range, 1-8 cycles). The median delivered dose intensity was 27 mg/m2/week for paclitaxel (range, 18-50 mg/m2/week) and 17 mg/m2/week (range, 12-39 mg/m2/week) for docetaxel. Six patients received schedule A1. This schedule was considered not feasible due to neutropenia grade > 2, mucositis, and diarrhea grade 2, which required dose reduction/omission in 33{\%} of administrations. For this reason, treatment in the following 5 patients was omitted on day 15 (schedule A2). Schedule B was found to be more feasible with 16{\%} of dose reductions/omissions. The overall response rate was 68{\%} (95{\%}Cl, 50{\%}-86{\%}) with a median duration of response of 10 months (range, 2-18+ months). Treatment was well tolerated; myelosuppression was rare and grade 3 cutaneous toxicity was observed in only 2 patients. In conclusion, weekly docetaxel/paclitaxel is active at low dosages and was well tolerated as salvage chemotherapy in metastatic breast cancer. This regimen represents a valid option as a salvage treatment in taxane- and anthracycline-pretreated patients.",
keywords = "Antracyclines, Granulocyte colony-stimulating factor, Neutropenia, Salvage chemotheraphy, Taxane",
author = "Alessandra Gennari and Valentina Guarneri and Elisabetta Landucci and Cinzia Orlandini and Marianna Rondini and Barbara Salvadori and Sergio Ricci and Conte, {Pier Franco}",
year = "2002",
language = "English",
volume = "3",
pages = "346--352",
journal = "Clinical Breast Cancer",
issn = "1526-8209",
publisher = "Elsevier",
number = "5",

}

TY - JOUR

T1 - Weekly docetaxel/paclitaxel in pretreated metalistic breast cancer

AU - Gennari, Alessandra

AU - Guarneri, Valentina

AU - Landucci, Elisabetta

AU - Orlandini, Cinzia

AU - Rondini, Marianna

AU - Salvadori, Barbara

AU - Ricci, Sergio

AU - Conte, Pier Franco

PY - 2002

Y1 - 2002

N2 - The purpose of our study was to evaluate the feasibility and efficacy of weekly docetaxel/paclitaxel in pretreated advanced breast cancer patients. Twenty-six patients with metastatic breast cancer were included in this study. Three different schedules of treatment were administered. The starting schedule, A1, consisted of docetaxel 60 mg/m2 on day 1 plus paclitaxel 60 mg/m2 over 1 hour, weekly for 18 weeks; this schedule was considered feasible if at least 70% of the planned doses were given on time and without reduction. Schedule A2 consisted of the same doses administered on days 1 and 8 every 3 weeks, and schedule B consisted of docetaxel 25 mg/m2 followed by paclitaxel 40 mg/m2 for 1 hour on days 1 and 8 every 3 weeks for a total of 6 cycles. All patients had received prior anthracyclines, and 19 patients were pretreated with taxanes. Seventy-seven percent of patients had received at least 2 prior lines of chemotherapy. Twenty-five patients are assessable for toxicity and efficacy. A total of 109 cycles of chemotherapy have been administered, with a median of 4 cycles per patient (range, 1-8 cycles). The median delivered dose intensity was 27 mg/m2/week for paclitaxel (range, 18-50 mg/m2/week) and 17 mg/m2/week (range, 12-39 mg/m2/week) for docetaxel. Six patients received schedule A1. This schedule was considered not feasible due to neutropenia grade > 2, mucositis, and diarrhea grade 2, which required dose reduction/omission in 33% of administrations. For this reason, treatment in the following 5 patients was omitted on day 15 (schedule A2). Schedule B was found to be more feasible with 16% of dose reductions/omissions. The overall response rate was 68% (95%Cl, 50%-86%) with a median duration of response of 10 months (range, 2-18+ months). Treatment was well tolerated; myelosuppression was rare and grade 3 cutaneous toxicity was observed in only 2 patients. In conclusion, weekly docetaxel/paclitaxel is active at low dosages and was well tolerated as salvage chemotherapy in metastatic breast cancer. This regimen represents a valid option as a salvage treatment in taxane- and anthracycline-pretreated patients.

AB - The purpose of our study was to evaluate the feasibility and efficacy of weekly docetaxel/paclitaxel in pretreated advanced breast cancer patients. Twenty-six patients with metastatic breast cancer were included in this study. Three different schedules of treatment were administered. The starting schedule, A1, consisted of docetaxel 60 mg/m2 on day 1 plus paclitaxel 60 mg/m2 over 1 hour, weekly for 18 weeks; this schedule was considered feasible if at least 70% of the planned doses were given on time and without reduction. Schedule A2 consisted of the same doses administered on days 1 and 8 every 3 weeks, and schedule B consisted of docetaxel 25 mg/m2 followed by paclitaxel 40 mg/m2 for 1 hour on days 1 and 8 every 3 weeks for a total of 6 cycles. All patients had received prior anthracyclines, and 19 patients were pretreated with taxanes. Seventy-seven percent of patients had received at least 2 prior lines of chemotherapy. Twenty-five patients are assessable for toxicity and efficacy. A total of 109 cycles of chemotherapy have been administered, with a median of 4 cycles per patient (range, 1-8 cycles). The median delivered dose intensity was 27 mg/m2/week for paclitaxel (range, 18-50 mg/m2/week) and 17 mg/m2/week (range, 12-39 mg/m2/week) for docetaxel. Six patients received schedule A1. This schedule was considered not feasible due to neutropenia grade > 2, mucositis, and diarrhea grade 2, which required dose reduction/omission in 33% of administrations. For this reason, treatment in the following 5 patients was omitted on day 15 (schedule A2). Schedule B was found to be more feasible with 16% of dose reductions/omissions. The overall response rate was 68% (95%Cl, 50%-86%) with a median duration of response of 10 months (range, 2-18+ months). Treatment was well tolerated; myelosuppression was rare and grade 3 cutaneous toxicity was observed in only 2 patients. In conclusion, weekly docetaxel/paclitaxel is active at low dosages and was well tolerated as salvage chemotherapy in metastatic breast cancer. This regimen represents a valid option as a salvage treatment in taxane- and anthracycline-pretreated patients.

KW - Antracyclines

KW - Granulocyte colony-stimulating factor

KW - Neutropenia

KW - Salvage chemotheraphy

KW - Taxane

UR - http://www.scopus.com/inward/record.url?scp=0036970903&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036970903&partnerID=8YFLogxK

M3 - Article

VL - 3

SP - 346

EP - 352

JO - Clinical Breast Cancer

JF - Clinical Breast Cancer

SN - 1526-8209

IS - 5

ER -